Nutritional support in hospitalised patients with diabetes and risk for malnutrition: a secondary analysis of an investigator-initiated, Swiss, randomised controlled multicentre trial

被引:0
|
作者
Keller, Bettina [1 ]
Wunderle, Carla [1 ]
Tribolet, Pascal [1 ]
Stanga, Zeno [2 ]
Kaegi-Braun, Nina [3 ]
Mueller, Beat [4 ,5 ]
Schuetz, Philipp [1 ]
机构
[1] Kantonsspital Aarau AG, Aarau, Switzerland
[2] Univ Bern, Fac Med, Bern, Switzerland
[3] Karolinska Inst, Stockholm, Sweden
[4] Univ Basel, Med Fac, Dept Clin Res, Basel, Switzerland
[5] Cantonal Hosp Aarau, Med Univ Dept, Clin Endocrinol, Aarau, Aargau, Switzerland
来源
BMJ OPEN | 2024年 / 14卷 / 08期
基金
瑞士国家科学基金会;
关键词
Nutritional support; NUTRITION & DIETETICS; Randomized Controlled Trial; DIABETES & ENDOCRINOLOGY; MEDICAL INPATIENTS; CLINICAL-OUTCOMES; MELLITUS; PREVALENCE; INFECTION; FORMULAS; COVID-19; PEOPLE; OLDER;
D O I
10.1136/bmjopen-2024-084754
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The main objective of this study was to investigate the effects of nutritional support on mortality in hospitalised patients with diabetes and nutritional risk participating in the Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) trial. Design Secondary analysis of a Swiss-wide multicentre, randomised controlled trial. Participants Patients with diabetes and risk for malnutrition. Interventions Individualised nutritional support versus usual care. Primary outcome measure 30-day all-cause mortality. Results Of the 2028 patients included in the original trial, 445 patients were diagnosed with diabetes and included in this analysis. In terms of efficacy of nutritional therapy, there was a 25% lower risk for mortality in patients with diabetes receiving nutritional support compared with controls (7% vs 10%, adjusted HR 0.75 (95% CI 0.39 to 1.43)), a finding that was not statistically significant but similar to the overall trial effects with no evidence of interaction (p=0.92). Regarding safety of nutritional therapy, there was no increase in diabetes-specific complications associated with nutritional support, particularly there was no increase in risk for hyperglycaemia (adjusted OR 0.97, 95% CI 0.56 to 1.67 p=0.90). Conclusion Patients with diabetes and malnutrition in the hospital setting have a particularly high risk for adverse outcomes and mortality. Individualised nutritional support reduced mortality in this secondary analysis of a randomized trial, but this effect was not significant calling for further large-scale trials in this vhighly ulnerable patient population.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial
    Ichijima, Ryoji
    Ikehara, Hisatomo
    Yamaguchi, Daisuke
    Nagata, Yasuhiko
    Ogura, Kanako
    Esaki, Mitsuru
    Minoda, Yosuke
    Ono, Hiroyuki
    Maeda, Yuki
    Kiriyama, Shinsuke
    Sumiyoshi, Tetsuya
    Kanmura, Yuichi
    Gotoda, Takuji
    DIGESTIVE ENDOSCOPY, 2024, 36 (09) : 995 - 1002
  • [22] Protein is an important component of nutritional support predicting complications in malnourished hospitalised patients - Details of our previous randomised controlled trial (RCT)
    Drommer, Juliane
    Schneider, Heinz
    Alteheld, Birgit
    Stehle, Peter
    Meier, Remy
    CLINICAL NUTRITION ESPEN, 2015, 10 (03) : E124 - E128
  • [23] Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
    Tanaka, Kosuke
    Kessoku, Takaomi
    Yamamoto, Atsushi
    Takahashi, Kota
    Kasai, Yuki
    Ozaki, Anna
    Iwaki, Michihiro
    Kobayashi, Takashi
    Yoshihara, Tsutomu
    Misawa, Noboru
    Kato, Takayuki
    Arimoto, Jun
    Fuyuki, Akiko
    Sakai, Eiji
    Higurashi, Takuma
    Chiba, Hideyuki
    Hosono, Kunihiro
    Yoneda, Masato
    Iwasaki, Tomoyuki
    Kurihashi, Takeo
    Nakatogawa, Machiko
    Suzuki, Ayao
    Taguri, Masataka
    Oyamada, Shunsuke
    Ariyoshi, Keisuke
    Kobayashi, Noritoshi
    Ichikawa, Yasushi
    Nakajima, Atsushi
    BMJ OPEN, 2022, 12 (05):
  • [24] Cost Analysis in RAPSID: Randomised Controlled Trial of Peer Support in Diabetes
    Simmons, David
    Wingate, La'Marcus
    Holman, Daniel
    Graffy, Jonathan P.
    DIABETES, 2015, 64 : A80 - A81
  • [25] Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial
    Kiszka-Kanowitz, Marianne
    Theede, Klaus
    Thomsen, Sandra Bohn
    Bjerrum, Jacob Tveiten
    Brynskov, Jorn
    Gottschalck, Ida Benedikte
    Akimenko, Elena
    Hilsted, Karen Lisa
    Neumann, Anders
    Wildt, Signe
    Larsen, Lone
    Munk, Jens Kristian
    Ibsen, Per Holger
    Janjua, Huma Gul Rehana
    Gluud, Lise Lotte
    Mertz-Nielsen, Anette
    ECLINICALMEDICINE, 2022, 45
  • [26] Routine oral nutritional supplementation for stroke patients in hospital (FOOD): a multicentre randomised controlled trial
    Dennis, M
    Lewis, SC
    Warlow, C
    LANCET, 2005, 365 (9461): : 755 - 763
  • [27] Securing All intraVenous devices Effectively in hospitalised patients-the SAVE trial: study protocol for a multicentre randomised controlled trial
    Rickard, Claire M.
    Marsh, Nicole
    Webster, Joan
    Playford, E. Geoffrey
    McGrail, Matthew R.
    Larsen, Emily
    Keogh, Samantha
    McMillan, David
    Whitty, Jennifer A.
    Abu Choudhury, Md
    Dunster, Kimble R.
    Reynolds, Heather
    Marshall, Andrea
    Crilly, Julia
    Young, Jeanine
    Thom, Ogilvie
    Gowardman, John
    Corley, Amanda
    Fraser, John F.
    BMJ OPEN, 2015, 5 (09):
  • [28] Response to "Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial
    Ichijima, Ryoji
    Esaki, Mitsuru
    Ikehara, Hisatomo
    DIGESTIVE ENDOSCOPY, 2024, 36 (11) : 1281 - 1281
  • [29] Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial
    Bauer, Axel
    Sappler, Nikolay
    von Stulpnagel, Lukas
    Klemm, Mathias
    Schreinlechner, Michael
    Wenner, Felix
    Schier, Johannes
    Al Tawil, Amani
    Dolejsi, Theresa
    Krasniqi, Aresa
    Eiffener, Elodie
    Bongarth, Christa
    Stuhlinger, Markus
    Huemer, Martin
    Gori, Tommaso
    Wakili, Reza
    Sahin, Riza
    Schwinger, Robert
    Lutz, Matthias
    Luik, Armin
    Gessler, Nele
    Clemmensen, Peter
    Linke, Axel
    Maier, Lars S.
    Hinterseer, Martin
    Busch, Mathias C.
    Blaschke, Florian
    Sack, Stefan
    Lennerz, Carsten
    Licka, Manuela
    Tilz, Roland R.
    Ukena, Christian
    Ehrlich, Joachim R.
    Zabel, Markus
    Schmidt, Georg
    Mansmann, Ulrich
    Kaab, Stefan
    Rizas, Konstantinos
    Massberg, Steffen
    LANCET DIGITAL HEALTH, 2022, 4 (02): : E105 - E116
  • [30] Investigator-initiated, multicentre, open-label, two-arm, randomised controlled trial comparing intubating conditions in 25° head-up position and supine: the InSize25 study protocol
    Falempin, Anne-Sophie
    Pereira, Bruno
    Binakdane, Fatima
    Bazin, Jean-Etienne
    Smirdec, Margot
    BMJ OPEN, 2019, 9 (11):